A major paradigm shift in federal drug policy is underway! The executive branch is taking significant steps to accelerate the research and development of psychedelic therapies, with a particular focus on Ibogaine for opioid addiction. This new initiative isn’t just talk; it includes a substantial financial commitment—matching state research investments with $50 million in federal grants (via ARPA-H). A breakdown of the administration’s strategy: 💊 Ibogaine for Opioid Use Dis